Claims
- 1. A method comprising determining a need for suppressing or enhancing attentive cognition in a mammal, and administering a compound that modulates carbonic anhydrase activity in the brain in an amount sufficient to suppress or enhance attentive cognition.
- 2. The method of claim 1, wherein the compound inhibits carbonic anhydrase activity in the brain and suppresses attentive cognition.
- 3. The method of claim 2, wherein the compound is selected from the group consisting of acetazolamide, benzolamide, and analogs thereof.
- 4. The method of claim 2, wherein the compound prevents establishment of a theta rhythm.
- 5. The method of claim 2, wherein the compound prevents formation of associative memory.
- 6. The method of claim 2 wherein the suppression of attentive cognition is specific.
- 7. The method of claim 1 wherein the compound modulates intraneuronal carbonic anhydrase activity.
- 8. The method of claim 1, wherein the compound modulates extraneuronal carbonic anhydrase activity.
- 9. The method of claim 1, wherein the compound alters neuronal HCO3− conductance.
- 10. The method of claim 1, wherein the compound modulates a neuronal HCO3− current relative to neuronal Cl− and/or K+ currents.
- 11. The method of claim 1, wherein the compound strengthens theta rhythm in the mammal.
- 12. The method of claim 1, wherein the compound promotes synaptic transformation in the mammal.
- 13. The method of claim 1, wherein the compound increases or decreases bicarbonate-mediated GABAergic depolarization.
- 14. A method of improving attentive cognition in a patient comprising determining the need for improved attentive cognition, and administering to the patient a compound that stimulates carbonic anhydrase activity in the brain in an amount sufficient to improve attentive cognition.
- 15. The method of claim 14, wherein the patient has no neurodegenerative disease or disorder.
- 16. The method of claim 14, wherein the patient suffers from a neurodegenerative disease or disorder.
- 17. The method of claim 14, wherein the compound stimulates intraneuronal carbonic anhydrase activity.
- 18. A method for treating a neurological disease or disorder comprising administering a stimulator of brain carbonic anhydrase activity in an amount effective to improve attentive cognition.
- 19. The method of claim 18, wherein attention and/or memory acquisition is enhanced.
- 20. The method of claim 18, wherein the neurological disease or disorder is selected from dementia, stroke, hypoxia, and ischemia.
- 21. A method for screening compounds for usefulness for cognitive enhancement therapy comprising measuring the effect of a compound on carbonic anhydrase activity in neurons, in tissue, in animals, or in cell culture, and selecting those compounds that stimulate carbonic anhydrase activity.
- 22. The method of claim 21, further comprising measuring the effect of the compound on theta rhythm in neurons, in tissue, in animals, or in cell culture and selecting those that strengthen a theta rhythm.
- 23. The method of claim 21, further comprising measuring the effect of the compound on synaptic transformation.
- 24. The method of claim 21, further comprising measuring the effect of the compound on attentive cognition.
- 25. A pharmaceutical product comprising a dosage form comprising a pharmaceutically acceptable carrier and a compound that inhibits or stimulates carbonic anhydrase activity in the brain, associated with labeling indicating use of the dosage form for cognitive effects.
- 26. A method of stimulating synaptic transformation of inhibitory postsynaptic potentials into excitatory postsynaptic potentials in GABAergic synapses in a mammalian brain, comprising administering to the brain an activator of intraneuronal carbonic anhydrase activity, thereby stimulating the synaptic transformation in the synapses.
- 27. The method of claim 26, wherein the synapses are in pyramidal cells in the hippocampal region.
- 28. A method of blocking synaptic transformation of inhibitory postsynaptic potentials into excitatory postsynaptic potentials in GABAergic synapses in a mammalian brain, comprising determining a need for blocking, and administering to the brain an inhibitor of intraneuronal carbonic anhydrase activity, thereby blocking the synaptic transformation in the synapses.
- 29. The method of claim 28, wherein the inhibitor neutralizes the excitatory effects of calexcitin.
- 30. The method of claim 28, wherein the inhibitor is acetazolamide or an analog of acetazolamide.
- 31. The method of claim 28, wherein the synapses are in pyramidal cells in the hippocampal region.
Parent Case Info
[0001] This application claims the benefit of U.S. provisional application Ser. No. 60/209,970, filed Jun. 7, 2000, incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60209760 |
Jun 2000 |
US |